We have observed
5 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after
January 19, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
POLYSACCHARIDES COMPRISING TWO ANTITHROMBIN III-BINDING SITES, PREPARATION THEREOF AND USE THEREOF AS ANTITHROMBOTIC MEDICAMENTS
SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
IDRABIOTAPARINUX FOR THE TREATMENT OF PULMONARY EMBOLISM AND FOR THE SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS
PYRAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF BLADDER CANCER